ENOB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Aug 2023 @ 15:58):

Stats
Today's Volume	87 289.00
Average Volume	254 603
Market Cap	45.38M
EPS	$-698 421 ( 2023-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.344
ATR14	$0.193 (7.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-23	Miller Avram	Buy	1 000 000	Common Stock
2023-10-23	Miller Avram	Buy	27 147	Option to purchase shares of common stock
2023-10-11	Miller Avram	Buy	0
2023-10-04	Hendriks Ruud	Buy	16 129	Option to purchase shares of common stock
2023-10-04	Boeren Leni	Buy	16 129	Option to purchase shares of common stock

INSIDER POWER
93.82
Last 80 transactions
Buy: 35 900 381 \| Sell: 26 846 213

Volume Correlation

Long: 0.11 (neutral)

Short: -0.07 (neutral)

Signal:(77.816) Neutral

Enochian Biosciences Inc Correlation

10 Most Positive Correlations
UK	0.894
GAINL	0.893
MRACW	0.892
AYLA	0.891
KBSF	0.887
GRNV	0.885
ISNS	0.884
BIOL	0.879
VIH	0.874
OPTN	0.866

10 Most Negative Correlations
BOCH	-0.92
ALPN	-0.918
SGH	-0.904
NXGL	-0.903
ELTK	-0.902
AMAT	-0.892
MOTNU	-0.889
STRR	-0.885
PEBK	-0.885
PLAB	-0.883

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enochian Biosciences Inc Correlation - Currency/Commodity

-0.10
( neutral )

-0.02
( neutral )

0.00
( neutral )

-0.26
( neutral )

-0.51
( weak negative )

0.41
( neutral )

Enochian Biosciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-705 302

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.16

Financial Reports:

No articles found.

Enochian Biosciences Inc

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.